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referred to the nearest Designated Microscopy 
Cen-ter (DMC) or their sputum was collected and 
trans-ported to the DMC and those found to be TB 
were started on DOTS medicines as per the 
program treat-ment guidelines.  
Results and lessons learnt: Of 1606 slum population 
and 1420 refugees visited, 43 (2.7%) and 34 (2.4%) 
were found to have cough for more than 2 weeks. Of 
them, 38 (88%) and 32(94%) got themselves tested and 
4 and 3 sputum positive pulmonary TB were 
subsequently started on treatment.  
Conclusions and key recommendations: The 
above findings highlight the importance and necessity 
of conducting periodic outreach activities among the 
vulnerable (slum) and marginalized (refugees) popu-
lation. These groups usually have lack/limited access 
to TB diagnostic services. Seeking diagnosis for their 
symptoms could receive low priority for these popu-
lations who encounter other social challenges, result-
ing in delayed diagnosis and worsening of the 
disease. The above activities resulted in early 
diagnosis among these groups which would help in 
reducing the trans-mission in the community. The 
process served to reach across to these populations 
with basics of TB and facilitated linkages of these 
communities with the health system. 
 
PC-482-01 Tuberculosis among the 
Roma population in Macedonia  
M Trajcevska, A Sandevski, Lj Simonovska. Clinical 
Sector, Institute of Lung Diseases and Tuberculosis, 
Skopje, Macedonia, Yugoslav Republic. 
e-mail: drtrajchevska@yahoo.com 
 
Introduction: The latest data by WHO show that 
80% of TB cases in Europe are in the countries 
which have numerous Roma population. The 
number of Roma in Macedonia is 53 870 (2.66%).  
Aim: To fi nd out what is their participation in the 
total number of TB patients, what is their incidence 
and are they a risk group for TB and possible 
reasons for that.  
Patients and methods: For this purpose we analyzed 
data in latest six (6) years with special accent on Roma 
population with TB (sex, age, incidence).  
Results: We had 563 patients with TB in 2007; the 
incidence was 27.8/100 000 for general population, 
but the incidence for Roma people was 74.2/100 000. 
The next year incidence in Roma population was 
59.4/100 000 and in general population 23.8/100 000. 
In 2009 the incidence in Roma population was 42.6/ 
100 000 and in general population 23.4/100 000. The 
next year the incidence in Roma people was 70.5/ 100 
000 and in general population 20.8/100 000. In 2011 
the incidence in Roma people was 51.9/100 000 and 
in general population 17.9/100 000. The last year 
there were 356 regsitrated TB patients in the country 
with incidence of 17.2/100 000. The incidence of 
Roma people was 46.4/100 000. 
 
 
Conclusions: Roma are more vulnerable community. 
They are risk group for TB because their incidence is 
three times higher than in general population. Possible 
reasons for this are: substandard living conditions, lack of 
education and low rate of employment. 
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Background: With increasing life expectancy in In-
dia, there has been an increase in elderly population. 
Since elderly population are a vulnerable group for 
tuberculosis (TB) and there is paucity of data about 
the manifestation and outcomes of TB among this 
group, we undertook a study to describe and com-
pare the socio-demographic and clinical characteris-
tics and treatment outcomes of elderly (60 years and 
above) as compared to younger (15 to 59 years) TB 
patients registered in Revised National Tuberculosis 
Control Program (RNTCP) and to identify the risk 
factors associated with poor treatment outcomes 
among the elderly.  
Design/methods: We conducted a retrospective co-
hort study involving review of routinely maintained 
RNTCP records from July to September 2011, in fi ve 
districts of Western Uttar Pradesh (population: 40 
million). World Health Organization (WHO) rec-
ommended disease classification and treatment out-
come definitions are used by RNTCP. Qualitative data 
was expressed as proportions, χ
2
 test and relative risk 
along with 95% confidence intervals (CI) were calcu-
lated to analyse the association between outcome 
and potential predictor variables.  
Results: Of 2472 TB patients, 821 (33.2%) were 
el-derly, 1656 (67%) were males 81.7% resided in 
rural areas and 80% were new cases. Among the 
elderly TB patients, 22% had unsuccessful (death, 
default, fail-ure and transfer out) outcomes as 
against 14.5% in the comparison group (P < 0.001). 
Factors signifi-cantly associated with unsuccessful 
outcomes among elderly group were living in an 
urban area (RR = 2.33, 95%CI 1.77–3.07), history 
of a previous treat-ment (RR = 1.7, 95%CI 1.29–
2.23) and non-conver-sion of smear at end of 
intensive phase (RR = 4.37, 95%CI 2.27–8.42).  
Conclusion: Elderly TB patients had poorer treat-
ment outcomes as compared to the younger TB pa-
tients. This could be due to associated co-morbidities
 
